Background: Infantile Hemangioma (IH) is one of the most common childhood neoplasm. Current treatments for children with endangering Infantile Hemangioma are limited, and include primarily oral corticosteroid which has many systemic adverse effects. Furthermore, approximately one third of IH does not respond to oral steroids, prompting active investigations for new treatments.
Introduction:
Hemangiomas are defined as benign neoplasm composed of proliferative and hyperplastic vascular endothelium. Although most of these tumors are small and innocuous, some may be life or functionthreatening or have associated structural congenital anomalies 1 .
IH is also, perhaps, the least understood. This is, in part, due to from a long history of confusing nomenclature for vascular anomalies that employed classification schemes based on superficial descriptions of the lesions. 2 The 1 st major step toward clarifying this nomenclatural confusion was made by Mulliken and Glowacki in 1982 which was adopted by the International Society for the Study of Vascular Anomalies (ISSVA) in 1996. The term "Infantile Hemangioma" or "Hemangioma of infancy" is the preferred and accepted term. 1 Considerable controversy exists as to the management of IHs. The major goals of management of IH have recently been outlined in the Guidelines of Care for Haemangioma of Infancy by the American Academy of Derma-tology. 3 Medical therapies have become the mainstay in the mana-gement and treatment of IHs. Since 1970, oral steroids have been the standard therapy worldwide for serious or life-threatening IH cases. Oral Prednisolone or prednisone was commonly used as systemic steroid. Prednisolone accelerates the involution of Infantile Hemangiomas through differentiation and inhibition of angiogenesis 4 .But only one third patient responds to systemic steroid. Moreover, these patients are at increased risk for infection, peptic ulceration, poor wound healing, stunted growth, and behavioural changes (crying, insomnia, irritability). Several authors have reported successful management of IH by systemic steroid, with potentially serious side effects. At present, oral steroid therapy has proven to be very effective in reducing the size of the lesion. 5 Mazzola 6 first reported the use of intralesional steroid injection for the treatment of IHs in detail. Subsequently, other reports have appeared indicating good results with this technique. Many steroids were used as intralesional injection by many researchers. Most of the researchers used short actiong corticosteroid -injection Triamcinolone or diluted injection Triamcinolone .Some researchers used combination of short and long acting intralesional corticosteroids (Triamcenolone + Betamethasone) 6, 7, 8 Data about the use of long acting corticosteroidsinjection Dexamethasone for treatment of IH in vivo is lacking. But Hasan & co-worker's 3 study showed that both Prednisolone and Dexamethasone cause inhibition of neovessel growth in IH tissue in vitro.
In Bangladesh , randomized clinical trials and evidence based studies on the efficacy of newer modalities of treatment is still lacking . Keeping these facts in mind and getting idea from Hasan & coworker's study, this comparative study was done to find out a cheap and effective modality of treatment with minimum side effects for treatment of IH . We compared the effectiveness and complications of intralesional injection of Dexamethasone with that of the oral Prednisolone in treatment of smaller sized IH.
Materials and Methods:
It was a prospective study conducted on patients of IH who were treated with intralesional Dexamethasone or oral Prednisolone and was carried out in the Department of Pediatric Surgery, Chittagong Medical College & Hospital, Chittagong, Bangladesh from January 2011 to December 2012.
Patient's age limit was 1 day to 12 years. The participating patients were divided into two groups: Group A-Patients were treated with Oral Prednisolone and Group B-Patients were treated with IL Dexamethasone. Each group was divided according to age into-Neonate (1-28 days),Infant ( 29 days to 1 year) and Children (2 nd year to 12 years). During the study period only one neonate came, so it was excluded.
Sample size were 48 (n= 48). Among them twenty six patients were selected in group A (n 1= 26) and twenty two patients were selected in group B (n 2= 22). Inclusion Criteria were: Single IH with a volume of d" 54 cubic cm, patients who came for regular follow up up to 48 wks after starting treatment. Exclusion Criteria were: Multiple IH, patients who were treated before study period and Periorbital IH 4 .
Diagnosis was confirmed by color Doppler ultrasound. Ultrasound also gave measurement of the volume of lesion. Indications for the treatment were rapidly growing lesions, lesions causing pressure effect to surrounding structure, bleeding, ulceration and cosmetic concern. Site, Color and Volume of the lesions were noted. Infected and bleeding cases were given admission. Infection was controlled by proper antibiotic. Bleeding was controlled by pressure bandage or diathermy cauterization. Pictorial documentation was carried out after taking informed written consent. After starting treatment, all patients were followed up; 1st follow up after 2 weeks and then at every 4 weeks interval up to 48 weeks. In each follow up; volume of the lesion, weight of the patient, blood pressure and any complications & side effects that arose after starting treatment were noted.
For group A; choice of oral steroid was Tab Prednisolone (5 mg).H2 receptor blocker was given to all patients to prevent gastric irritation. Live attenuated vaccine was restricted during the treatment period. Starting dose was 2-3 mg/kg/day at full stomach and at morning .If no response within 2 weeks, dose was increased to 4-5 mg/kg/day. If no response with increased dose within next two weeks-treatment was stopped and these patients were considered as non responder. In case of responder, treatment continued till response of IH to oral Prednisolone persists .
In group B; IL Dexamethasone was given in a dose of 2 mg/kg body weight. The injection was given by a 26 ½ gauge needle and it was given directly into the IH in four directions (dividing the lesion in four quadrants by 2 imaginary lines perpendicular to each other) through the same needle puncture site. Direct pressure was applied with sterile gauze for 2 to 10 minutes until all bleeding had stopped. Injection was given at 4 weeks interval. If no response with 3 successive injection, treatment was stopped and patients were considered as non responder. In case of responders , IL Dexamethasone was continued at 4 weeks interval and continued till response of IH persists.
In both groups, when volume of the IH and it's color remain constant in 2 successive follow up, it was considered as lack of response to treatment and oral prednisolone was tapered over 7 days and IL Dexamethasone was discontinued respectively. Follow up was continued up to 48 weeks. Injections were given directly into the IH in four directions (dividing the lesion in four quadrants by 2 imaginary lines perpendicular to each other) through the same needle puncture site. Direct pressure was applied with sterile gauze for 2 to 10 minutes until all bleeding had stopped.
In both groups, the response to the treatment was analysed by grading scale of Table-1 which was used by Gangopadhyay et al 7 with modification . All patients were followed up at 4 weeks interval. In each visit, we monitored volume (length x breadth x depth) of the lesion and its color change to evaluate the response of IH to treatment . The color changes were monitored by color code of figure-1 10 . Besides that, color Doppler study of the lesion and assessment were also made for any complication and side effect .At every follow up photograph of the lesion was taken and it was compared to previous photographs. Excellent-Near total disappearance (more than 75% of pre-treatment size) and color change from pretreatment state to color of surrounding normal skin (or near to normal skin color) of the patient.
Good -50% to 75% regression in size with color change from pretreatment state to code 3 (any one or in combination of grey and sandy brown) of figure 1.
Poor -25% to 50% regression in size with color change from pretreatment state to color code 2 (any one or in combination of dull purple and pink bow) of figure 1.
No -No reduction in size or <25% regression in size with no color change .
All data were compiled and edited meticulously .For analysis of data SPSS version 18 software was used.
Results were expressed as number and percent (%) of patients in contingency tables. The value of P < 0.05 was considered as statistically significant difference.
Results:
A total of 48 (forty eight) patients of IH were included in this study. Among them 26 patients were treated with oral Prednisolone and 22 patients were treated with intralesional injection of Dexamethasone. Out of 48 patients, there were 14 male and 34 female and male to female ratio was 1:2.43. In group A, there was 10 (38.5%) male and 16 (61.5%) female; and in group B there was 4 (18.2%) male and 18 (81.8%) female. Infants were the predominating age group in both groups.
In group A, 19 patients (69.2 %) and in group B, 15 patients (68.2%) responded to the treatment though there was no further proliferation of IH in the non responder group after starting treatment. Responses to treatment in both study groups were graded as excellent, good and poor according to Table 1 . Chi square (÷2) test was done to see the association between study groups and responses to treatments among the different age groups and it is shown in Table 2 . As P value is >0.05, the association was statistically not significant.
Therapeutic responses between 2 study groups according to anatomical site were shown in Table 3 .
In head and neck region, response was 66.7% in group A and in group B it was 63.6%.In upper limb, responses were 100% in group A and 66.7% in group B. Chi square (÷2) test was done to see the association between study groups and responses to treatments among the different anatomical site. 
Ï% NS = Not Significant
In group A, mean duration of treatment was 10.85± 5.48 weeks and in group B it was 12.91±4.26 weeks. Median duration of treatment in group A was 13 weeks and in group B it was 12 weeks. Table 4 is showing average length of treatment in both study groups . Here P value is statistically not significant. NS= not significant , S = significant
Discussion:
Infantile Hemangioma is one of the most misdiagnosed and maltreated clinical problems in Bangladesh.
In this study, we found that female patient were greater in number and male to female ratio was 1:2.43 like many other centers 6, 11 . In 48 patients of IH, we found that the most common age group was infant (64.8%).This data correlates with the study of Azizkhan 12 .
In our study, 69.2 % patient of group A responded (excellent = 57.7%, good = 3.8% and poor =7.7 %) to oral prednisolone. These findings are near to other studies of the world 4, 9 .On the other hand in group B, 68.2 % patient responded (excellent = 31.8%, good = 13.7% and poor = 22.7%) to Dexamethasone. Gangopadhyay et al 7 reported excellent result in 75% patient with intralesional Triamcinolone.
There was no statistical difference (P = 0.175) in grading of response of two study groups. We observed that, regression of IH was associated with lightening of color and decrease in volume. The lesion which was swollen above the surrounding skin surface before treatment, their swelling decrease when they respond to treatment. These findings were more marked in excellent responder. We found that color of the lesion at pre-treatment state became faded when they started to regress in size with treatment. We measured blood pressure of all patients at every follow up but hypertension was not detected at any follow up. None of the side effects were persistent and all the side effects disappeared soon after treatment was stopped. Children's Hospital of Wisconsin 12 reported a number of side effects with systemic corticosteroids including irritability, gastrointestinal upset, hypertension and growth retardation and most of the side effects accompany prolonged use of systemic steroid. Nieuwenhuis et al 5 reported that hypertension developed more quickly in patients given a higher initial dose. We gave higher dose of Prednisolone in nine patients and none of them developed hypertension. For defining hypertension we followed the "Report of the Second Task Force on Blood Pressure Control in Children 14 .
Klement and Fishman 4 reported rebound growth when withdrawn of oral Prednisolone was too rapid. In each follow up we measured size of the lesion and in no patient (both group A and B) we found rebound growth after stoppage of treatment.
On the other hand, side effects and complications were noted in 36.3% patient of group B. The commonest complication with intralesional Dexamethasone was ulceration at injection site (27.3%). Only one infant out of twenty two (4.5%) developed hypo pigmentation of skin and another one infant (4.5%) developed repeated bleeding from injection site. Chantharatanapiboon 6 reported side effects in 9.1% to 16% patient who were treated with intralesional Triamcinolone and commonest side effect was ulceration and skin hypo pigmentation.
In this study we found that 71.4% children of group A developed side effects and in group B only 16.7% children developed side effects and complications which is statistically significant (p=0.017).
Conclusion:
Intralesional injection of Dexamethasone can be used like oral Preadnisolone for the treatment of smaller sized IHs. Side effect of oral Prednisolone is more in children than injection Dexamethasone. To get optimum response, both Prednisolone and Dexamethasone should be used in patients below one year of age. Unlike oral Prednisolone, injection Dexamethasone is free from systemic side effects.
Recommendation:
Intralesional Dexamethasone is preferable to oral Prednisolone in small IH in infants.
